Unity Biotechnology (NASDAQ:UBX) finished after-hours trading up 8.3% after an initiation by Roth Capital at Buy.

The firm’s launching coverage with a $35 price target – a new Street-high target implying 297% upside.

Wall Street analysts overall are Bullish on the stock, as are Seeking Alpha authors; It has a Quant Rating of Neutral.


Source link